Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.00p -2.46% 238.00p 235.00p 245.00p 244.00p 240.00p 244.00p 62,362 16:35:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -17.2 -45.2 - 76

Reneuron Share Discussion Threads

Showing 7251 to 7274 of 7275 messages
Chat Pages: 291  290  289  288  287  286  285  284  283  282  281  280  Older
DateSubjectAuthorDiscuss
19/7/2019
16:20
Where is raytard
manc10
18/7/2019
18:45
wheres raytard
manc10
18/7/2019
01:46
This is a wonderful story for the patients involved: Https://www.bloomberg.com/news/articles/2019-04-17/-bubble-boys-cured-in-medical-breakthrough-using-gene-therapy Also for the investors: Https://www.bloomberg.com/news/articles/2019-04-17/mustang-bio-soars-after-novel-gene-therapy-cured-bubble-boys Shows what can happen when good news develops with a company's science.
lauders
17/7/2019
16:28
£3 ps 3 times in the last year?
bantam175
17/7/2019
15:11
Logically the share price at Amigo should drop tomorrow to adjust for the lost dividend - that's what usually happens - so it's not clear that it's a good trade unless you've got some other reason to buy.
supernumerary
17/7/2019
11:31
That might make sense about BAE or BAT but take a look at the awards amigo have won. Not a payday lender but painted with the same brush. Still. Each to their own. nearly 4% overnight is more than I could resist.
bantam175
17/7/2019
10:31
On moral grounds alone I wouldn’t touch Amigo.
rayrac
17/7/2019
09:16
Anyone interested Amigo going ex-div tomorrow on a 7.45p div. Currently around 180 per share.
bantam175
16/7/2019
12:03
its down again where is rayrac
manc10
16/7/2019
07:21
manc1014 Jul '19 - 18:22 - 6981 of 6983 (Filtered) Just do it?
rayrac
16/7/2019
01:32
Just filter him please small crow. The best solution to anyone who doesn't have anything constructive to contribute IMO. This doesn't tell us anything new but it sounds confident. Https://www.youtube.com/watch?v=WNDZIEFRtSg&feature=youtu.be Wonder what the definition of "near-term" is in Michael Hunt's opinion? Would be nice to see some more agreements signed now that Nick (last RNS) is on board and interesting he has been working with RENE for a while already! Edit: This is just one link I found in relation to Thomas Cook that was mentioned in the interview: Https://www.bloomberg.com/news/articles/2019-07-12/fosun-mulling-thomas-cook-deal-with-940-million-in-new-money
lauders
15/7/2019
10:59
Do you have anything interesting to say manc?
small crow
14/7/2019
18:22
Wow this stock has been hammered of late rayrac must own some
manc10
14/7/2019
17:22
Afternoon Freddie?! Sorry it took so long to reply.
algernon2
13/7/2019
09:30
FYI https://www.dailymail.co.uk/health/article-4110/Blindness-cure-sight.html
dickbush
13/7/2019
08:09
I also went back to see the BOD purchases since the capital reorganization took place at the beginning of January 2018. 27 Sept 2018 = Olav Hellebø, Chief Executive Officer - 14,936 @ 66.9p 27 Sept 2018 = Michael Hunt, Chief Financial Officer - 7,462 @ 67p 11 April 2019 = John Berriman, Non-executive Chairman - 80,000 @ 225p 11 April 2019 = Simon Cartmell OBE, NED - 7,758 @ 225.5516p 11 April 2019 = Professor Sir Chris Evans OBE, NED - 4,500 @ 221.5p 11 April 2019 = Dr Mike Owen, NED - 4,237 @ 236p 18 April 2019 = Professor Sir Chris Evans OBE, NED - 10,000 @ 228.7p So highest price 236p and lowest 66.9p. My only buy was around the average of Prof. Evans' purchases. I think that all the purchasers from 11th April on are expecting to benefit a lot more than they are now as the story unfolds. Sure hope so! Last time I did this was on the AMER BB and the BOD there invested a LOT more than the BOD here. In the meantime the share price there has declined pretty significantly despite the prospects, so over the short term BOD purchases don't necessarily mean a thing! Just wanted to post this as a reference for the BOD's "skin in the game" but some of them do have more than shown as they bought more in the years before. Here is a list of total holdings per the 2018 annual report: John Berriman - 10,434 (2018) 10,434 (2017) Olav Hellebø - 6,694 (2018) 6,694 (2107) Michael Hunt - 20,084 (2018) 20,084 (2017) Simon Cartmell OBE - 7,875 (2018) 7,875 (2017) Dr Tim Corn - 2,000 (2018) 2,000 (2017) Dr Claudia D’Augusta 0 (2018) 0 (2017) Professor Sir Chris Evans OBE - 240,105 (2018) 240,105 (2017) Dr Mike Owen - 0 (2018) 0 (2017) If Dr. Claudia buys any and Dr. Mike buys more we should all sit up and pay real attention! Good to see there have been some buys (see first part) this year and towards the end of last year to change the numbers in the last list when released again in the 2019 annual report!
lauders
13/7/2019
06:26
Had a chance to listen to the Preliminary Results presentation and a little happier to keep the faith and wait for developments here. Http://www.reneuron.com/investors/presentations/ (click on this link to register/log-in - Https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918/5d295c7c3ee32ca64a00052f ) On the hRPC front I was particularly pleased to hear (33.20 minutes/seconds in) that the RENE team are "not worrried about the duration of cell efficacy as they are new cells and are not diseased, but it is a matter of proving the point" and on the exosomes it would appear no deals will be made until Q4 from what was stated. hRPC is another matter! Again, another shareholding I have where patience (especially if Woodford decides to reduce more) is needed!
lauders
12/7/2019
16:59
https://www.bloomberg.com/news/articles/2019-07-12/woodford-is-said-to-weigh-sale-of-stake-in-subprime-lender-nsf?srnd=premium-europe
dickbush
12/7/2019
10:22
raytard come out come out where ever you are down she goes
manc10
12/7/2019
08:02
Yes, positive sign that.
small crow
12/7/2019
08:00
With luck the RNS today will let us recover some of yesterday's sell-off. Not sure why they couldn't release both together yesterday? Anyway, looks a good appointment and certainly seems to strongly indicate that discussions on agreements are ongoing as stated yesterday and again today. Perhaps nearer than we think?
lauders
11/7/2019
22:03
Well, up £9.2k at hur and had a third of it knocked off here...could have been worse!
rayrac
11/7/2019
19:47
By Mark RobinsonWe haven't covered ReNeuron's(RENE) results since the end of 2016, but given the share price has risen by 148 per cent over the past 12 months, an assessment of recent events is in order. In February, the company announced "strongly positive preliminary efficacy data" in relation to clinical trials for its hRPC (human retinal progenitor cells) stem-cell therapy candidate in retinitis pigmentosa, a rare degenerative condition involving a breakdown and loss of cells in the retina.RENE:LSEReNeuron Group PLC1mthToday change-11.82%Price (GBP)242.50All three patients in the study showed "a rapid improvement in vision compared with their pre-treatment baseline". In practical terms, it meant the patients could read an additional four lines of letters on the standard ETDRS (early treatment diabetic retinopathy study) eye chart. Results for all the patients will be presented at the American Academy of Ophthalmology annual meeting in October. Management notes that "an improvement of at least 15 letters from baseline is considered to be clinically meaningful by the US Food and Drug Administration".RENEURON (RENE)   ORD PRICE:248pMARKET VALUE:£79mTOUCH:245-250p12-MONTH HIGH:333pLOW: 48pDIVIDEND YIELD:nilPE RATIO:naNET ASSET VALUE:74pNET DEBT:£26.4mYear to 31 MarTurnover (£000)Pre-tax profit (£m)Earnings per share (p)Dividend per share (p)2015 †30.0-10.3-50.0nil2016 †29.0-12.8-40.0nil2017 †46.0-18.2-49.2nil201843.0-21.0-55.7nil201949.0-17.2-45.2nil% change+14---Ex-div:-   Payment:-   †EPS for 2015-2017 adjusted to take account of capital reorganisationIC ViewReNeuron also commenced patient dosing in the US placebo-controlled Phase IIb clinical trial of its CTX stem-cell therapy candidate in chronic stroke disability, with top-line data from the study due in late 2020. The clinical progress hasn't gone unnoticed. Chinese drugs heavyweight Fosun Pharma has agreed to license the hRPC and CTX therapies as part of a deal worth up to £80m. Financials are of secondary importance as ReNeuron progresses its clinical programme, although N+1 Singer anticipates that cash will run out by March 2022, so it's probable that the gene therapy specialist will be tapping markets at some point.
bigspuds
11/7/2019
17:06
Hope no-one followed that INDVR tip this morning. If anyone did they would already be down 25%.......:(
bigspuds
Chat Pages: 291  290  289  288  287  286  285  284  283  282  281  280  Older
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190721 10:32:40